- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 89
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
- Interventions
- Norethindrone acetate pretreatment, No pretreatment
- Drug · Other
- Lead sponsor
- Scott and White Hospital & Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Menorrhagia
- Interventions
- Intrauterine Ultrasound-Guided Radiofreq. Ablation System
- Device
- Lead sponsor
- Gynesonics
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 104
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Web-based data collection, Paper-based data collection
- Other
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Menorrhagia
- Interventions
- Tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
- Conditions
- Adenomyosis
- Interventions
- Epelsiban, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 13
- States / cities
- Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more
- Conditions
- Von Willebrand Factor Deficiency
- Interventions
- Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Estradiol/Norethindrone Acetate, Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more
- Conditions
- Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
- Interventions
- Laparoscopic hysterectomy, Abdominal hysterectomy
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Adenomyosis
- Interventions
- Vaginal Bromocriptine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 55 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Uterine Fibroid, Endometriosis
- Interventions
- Not listed
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 660 participants
- Timeline
- 2018 – 2020
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
- Conditions
- Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
- Interventions
- Levonorgestrel intrauterine system, Combined oral contraceptives
- Device · Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Von Willebrand Diseases
- Interventions
- recombinant von Willebrand factor, tranexamic acid
- Drug
- Lead sponsor
- Margaret Ragni
- Other
- Eligibility
- 13 Years to 45 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
- Conditions
- Uterine Fibroids, Endometriosis
- Interventions
- Relugolix Combination Tablet
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 120
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
- Conditions
- Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
- Interventions
- Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
- Procedure
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years to 40 Years · Female only
- Enrollment
- 15 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Contraception, Menorrhagia
- Interventions
- ESS305 (Essure, BAY1454032), NovaSure
- Device · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 21 Years to 50 Years · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Ocala, Florida • Decatur, Illinois + 14 more
- Conditions
- Uterine Fibroids, Menorrhagia, Endometriosis
- Interventions
- conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Menstrual Bleeding, Heavy
- Interventions
- Sample Collection and Endometrial Biopsy
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Tranexamic Acid
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 19 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Akron, Ohio + 2 more
- Conditions
- Uterine Fibroids
- Interventions
- Vilaprisan (BAY1002670), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 46
- States / cities
- Canyon Country, California • Encinitas, California • Huntington Park, California + 35 more
- Conditions
- Heavy Menstrual Bleeding, Fibroid Uterus
- Interventions
- Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
- Other · Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia